However, DKK1 inhibition may not affect tumor growth in all ovarian cancer cases, but its overexpression alters anti-tumor immune populations within the tumor microenvironment, suggesting that it may be a new therapeutic target in EOC, especially when used in combination with immune-modulatory therapy (Betella et al., 2020). The gene discussed is DKK1; the disease is ovarian carcinoma.